Another difference that may explain the less objective response of 177Lu-PSMA in salivary gland cancers is probably the lower PSMA-ligand uptake in the salivary gland tumours compared to prostate cancer lesions: a mean SUVmax 8.2 (range 3.5–12.5) versus 13.3 (range 0.7–122.5). This evidence concerns the gene FOLH1 and prostate carcinoma.